BridgeBio Pharma, Inc.

BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company operates through a distinctive decentralized hub-and-spoke model, where autonomous teams focus on individual disease conditions while a central hub provides shared clinical, regulatory, and commercial expertise. BridgeBio's commercial-stage pipeline includes Attruby (acoramidis), an oral small molecule transthyretin stabilizer for transthyretin-mediated amyloidosis cardiomyopathy, alongside late-stage programs for conditions including limb girdle muscular dystrophy, autosomal dominant hypocalcemia, achondroplasia, and Canavan disease. The company partners with leading academic institutions to advance early-stage research and accelerate the development of first-in-class treatments for underserved patient populations lacking adequate therapeutic options. BridgeBio's focused approach on genetic diseases with clear genetic drivers enables precision targeting at the disease source, positioning the company as a leader in precision medicine for rare genetic conditions.